A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

被引：0
|
作者：
William Schelman
Sherry Morgan-Meadows
Howard Bailey
Kyle Holen
James P. Thomas
Jens Eickhoff
Heidi Brandon
Kate Oliver
Dona Alberti
George Wilding
机构：
[1] University of Wisconsin Paul P. Carbone Comprehensive Cancer Center,
[2] Southern Cancer Center,undefined
[3] The Ohio State University Comprehensive Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Gemcitabine; Patupilone; Chemotherapy; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：727 / 733
页数：6
相关论文
共 50 条
  • [21] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Metaxas, Yannis
    Kahatt, Carmen
    Alfaro, Vicente
    Fudio, Salvador
    Zeaiter, Ali
    Plummer, Ruth
    Sessa, Cristiana
    Von Moos, Roger
    Forster, Martin
    Stathis, Anastasios
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 91 - 98
  • [22] Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
    Nardo, Mirella
    Gouda, Mohamed A.
    Reilley, Matthew J.
    Biter, Amadeo B.
    Lim, Joann
    Bean, Stacie A.
    Nguyen, Ly M.
    Bhosale, Priya R.
    Ager, Casey R.
    Couillault, Coline A.
    Piha-Paul, Sarina A.
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Yap, Timothy A.
    Naing, Aung
    Rodon, Jordi
    Subbiah, Vivek
    Karp, Daniel D.
    Curran, Michael A.
    Hong, David S.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (02) : 89 - 98
  • [23] Phase I trial of combination becatecarin and oxaliplatin in patients with advanced solid tumors
    Manda, S.
    Mauser, C.
    Bokar, J.
    Cooney, M.
    Brell, J.
    Krishnamurthi, S.
    Savvides, P.
    Ivy, P.
    Remick, S.
    Dowlati, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Irinotecan and gemcitabine in patients with solid tumors: Phase I trial
    Lima, CMSR
    Leong, SS
    Sherman, CA
    Perkel, JA
    Putman, T
    Safa, AR
    Green, MR
    ONCOLOGY-NEW YORK, 2002, 16 (05): : 19 - 24
  • [25] Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
    Mavroudis, D
    Kourousis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Vardakis, N
    Samonis, G
    Georgoulias, V
    SEMINARS IN ONCOLOGY, 2000, 27 (01) : 25 - 30
  • [26] Phase I Trial of Fixed-Dose Rate Gemcitabine in Combination with Bortezomib in Advanced Solid Tumors
    Luu, Thehang
    Chow, Warren
    Lim, Dean
    Koczywas, Marianna
    Frankel, Paul
    Cristea, Mihaela
    Margolin, Kim
    Doroshow, James H.
    Somlo, George
    Gaur, Shikha
    Yen, Yun
    Morgan, Robert J.
    ANTICANCER RESEARCH, 2010, 30 (01) : 167 - 174
  • [27] Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors
    Goel, R.
    Chen, E.
    Welch, S.
    Laurie, S.
    Siu, L.
    Jonker, D.
    Srinivasan, R.
    Wang, L.
    Ivy, P.
    Oza, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Phase I study of Mistletoe extract/gemcitabine combination treatment in patients with advanced solid tumors
    Mansky, P.
    Wallerstedt, D.
    Monahan, B.
    Lee, C.
    Sannes, T.
    Stagl, J.
    Blackman, M.
    Swain, S.
    Grem, J.
    ONKOLOGIE, 2008, 31 : 200 - 200
  • [29] A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors
    Sandler, A
    Raghavan, D
    Meropol, N
    Meyers, T
    Kindler, H
    Fox, S
    Perez, R
    Einhorn, LH
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1120 - 1120
  • [30] A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
    Ghalib, Mohammad H.
    Pulla, Mariano Provencio
    Luken, Maria J. De Miguel
    de Juan, Virginia Calvo
    Chaudhary, Imran
    Hammami, M. Bakri
    Vikash, Sindhu
    Maitra, Radhashree
    Martinez, Sara
    Kahatt, Carmen
    Extremera, Sonia
    Fudio, Salvador
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 481 - 491
12345